A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

King Faisal Specialist Hospital & Research Center

Status: Unknown

Conditions: Metastatic Colorectal Cancer

Treatments: Drug: Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab

Study type: Observational

Funder types: Other

Identifiers

NCT01311050

RAC# 2081-068

Details and patient eligibility

About

A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

Full description

A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

Enrollment: 46 estimated patients

Sex: All

Ages: 14 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with diagnosed Metastatic Colorectal Cancer

Exclusion criteria

• Patients with diagnosis other than Metastatic Colorectal Cancer